Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company dedicated to advancing life-changing medicines for rare disease patients across Europe, has announced the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This strategic milestone strengthens the company’s leadership team and management board as Avanzanite continues its expansion across Europe, positioning itself for long-term growth and new partnerships.
A Seasoned Financial Leader Joins Avanzanite

Mr. Omari brings over 20 years of extensive financial leadership experience within the pharmaceutical industry. Most recently, he served as CFO at Proteome Sciences plc and Paion AG, where he successfully secured more than €150 million in financing and played a pivotal role in establishing key commercial infrastructure across Europe. His early career foundation was built at KPMG, where he gained extensive expertise in financial operations, strategy, and auditing within the pharmaceutical and healthcare sectors.
Strengthening Avanzanite’s Leadership Team
“We are thrilled to welcome Abdel to our leadership team, which we proudly consider our ‘Champions League’,” said Adam Plich, Founder and CEO of Avanzanite. “His appointment marks the second executive hire this year, reinforcing our commitment to building a world-class leadership team. Abdel’s financial expertise will be critical as we continue to execute our innovative go-to-market strategy to commercialize and deliver orphan medicines to patients across Europe.”
Mr. Omari’s Role and Vision
As CFO, Mr. Omari will be responsible for overseeing all fiscal operations, focusing on optimizing resources, instilling financial discipline, and executing capital raises to support the company’s rapid expansion and strategic partnerships. His role will be crucial in ensuring financial stability as Avanzanite scales its operations across Europe, expands its market reach, and broadens its product portfolio.
“It is a great privilege to join and support its mission to address the unmet needs of rare disease patients,” said Mr. Omari. “With its highly dedicated team and impressive progress in bringing life-changing medicines to patients across Europe, I look forward to strengthening Avanzanite’s financial operations and contributing to the company’s next phase of growth, especially as we expand into new pan-European partnerships.”
Mr. Omari will be based at Avanzanite’s second headquarters in Maastricht, the Netherlands.
Avanzanite’s Growth and Expansion in the European Market
In 2024, Avanzanite continued its strong momentum in the European orphan drug market. The company has reached over 120 patients across 12 countries and generated revenue in six. With two authorized medicinal products in its portfolio, Avanzanite is poised to expand into 26 European countries, with ambitions to extend its reach to 32 nations while rolling out its new go-to-market model. The company is also actively broadening its product portfolio to provide essential treatments to rare disease patients in need.
Future Prospects and Strategic Growth
Avanzanite’s expansion is fueled by its commitment to bringing innovative solutions to the orphan drug market, addressing critical unmet needs for rare disease patients. The company’s strategic approach involves not only securing regulatory approvals and market access but also establishing strong partnerships that will drive sustainable long-term success. With a focus on innovation and patient access, Avanzanite is set to revolutionize the rare disease pharmaceutical landscape in Europe.
The appointment of Mr. Omari is a key step in Avanzanite’s journey toward becoming a market leader in the rare disease space. His financial acumen and strategic insight will play a crucial role in shaping the company’s financial framework, supporting its mission to transform the lives of patients suffering from rare diseases. As Avanzanite continues to evolve, its leadership team remains dedicated to pushing the boundaries of pharmaceutical innovation, ensuring that life-changing medicines reach those who need them most.